All In Biotech

Drug Trial Radar · NCT04977167

Clinical Trial of HG146 Administered to Subjects With Advanced Solid Tumors or Lymphoma

A Phase I Open Label Study of HG146 Alone /in Combination With PD-(L)1 Inhibitor Administered With and Without Anticancer Agents in Participants With Advanced Solid Tumors or Lymphoma

Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Sep 23, 2021

Primary completion

Jun 13, 2024

Study completion Dec 22, 2024

Sponsor

Lead sponsor
HitGen Inc.Industry
Sponsor type
Industry
First posted
Jul 26, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase I, open-label, repeat-dose, non-randomized, multicenter study to evaluate the safety, tolerability, and preliminary clinical activity and establish a recommended dose of HG146 administered orally (PO) alone (Part 1) or co-administered (Part 2) with PD-(L)1 inhibitor in subjects with refractory/relapsed solid tumors or Lymphoma. Part 1 consists of a dose escalation phae,Part2 consists of a dose escalation phase and a cohort expansion phase. In Part 1, escalating doses of HG146 will be evaluated as guided by the "3+3" approach. In Part 2A, escalating doses of HG146 in combination with PD-(L)1 inhibitor will be evaluated as guided by the "3+3" approach. In Part 2B, subjects will receive a single dose level of HG146 as identified based on data from Part 2, in combination with PD-(L)1 inhibitor . A total of approximately 96 subjects will be enrolled in this study, approximately 36 for dose escalation cohorts, and approximately 60 in the expansion cohorts.

Conditions

  • Solid Tumor
  • Lymphoma

Interventions

  • HG146Drug

    HG146 is available as Capsule at a unit dose strength of 5 mg and 10 mg.

  • PD-(L)1 antibodyDrug

    PD-(L)1 Antibody is available as solution for infusion or lyophilized powder for reconstitution to be administered Q3W. It will be administered as an IV infusion for 30 minutes.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part I:Dose-Limiting Toxicities (DLTs)Time frame: Up to 26 Days in Cycle 0 and Cycle 1
  2. Part I:Serious Adverse Events (SAEs) and Adverse Events (AE)Time frame: Up to 2 years
  3. Part I:Maximum tolerated dose or Recommended Phase Ib dose (RP2D) of HG146Time frame: Up to 2 years
  4. Part 2A: Dose-Limiting Toxicities (DLTs) According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI-CTCAE v.5.0)Time frame: Up to 21 Days in Cycle 1
  5. Part 2A: Serious Adverse Events (SAEs) and Adverse Events (AE)Time frame: Up to 2 years
  6. Part 2A:Maximum tolerated dose or Recommended Phase II dose (RP2D) of HG146 in combination with PD-(L)1 antibodyTime frame: Up to 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • National Cancer Center/Cancer Hospital

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.